Close menu




November 26th, 2025 | 07:00 CET

Two new mines in 12 months – Analysts give the thumbs up: Almonty, MP Materials, Rheinmetall

  • Mining
  • Tungsten
  • Defense
  • CriticalMetals
  • Investments
Photo credits: pixabay.com

The rush for shares in defense and strategic metals drove prices in 2025. However, the market also gave premature praise. In the case of companies such as MP Materials and Rheinmetall in particular, the market has already anticipated many future revenues. Tungsten producer Almonty Industries is also one of the stock market winners of the year. However, the difference between Almonty and other stocks in the critical metals sector that have risen sharply is that Almonty will also be making a significant operational impact in 2025. The Sangdong mine in South Korea is considered a groundbreaking project for the supply of critical raw materials. The last time a mine of this size went into production was in the 1970s. What opportunities does this mega-project offer investors?

time to read: 3 minutes | Author: Nico Popp
ISIN: ALMONTY INDUSTRIES INC. | CA0203987072 , MP MATERIALS CORP | US5533681012 , RHEINMETALL AG | DE0007030009

Table of contents:


    Almonty ahead of Sangdong production start – three times higher grades than competitors

    Almonty's share price has climbed by more than 400% in the current year. Nevertheless, analysts still see upside potential based on the current price. Just earlier this week, analysts at Sphene Capital raised their long-term price forecast from CAD 8.40 to CAD 13.50. Almonty shares are currently trading at around CAD 8 - the reasons: the sharp rise in tungsten prices and the newly created capacity at Almonty. The Company is set to begin production at its Sangdong mine in South Korea this year and recently acquired Browns Lake, a tungsten project in the US state of Montana, which it plans to bring into production in 2026. This situation offers great upside potential – many other suppliers of critical metals are still a long way from production or only have one mine. Almonty is expected to have a total of three highly profitable production facilities by the end of 2026.

    The massive Sangdong project is central to Almonty's prospects. Immediately after production starts later this year, the mine is to be expanded within two years. The capacity will then be so large that Sangdong alone is expected to account for 40% of the tungsten produced outside China. Sangdong is considered one of the highest-grade tungsten deposits in the world, with an average grade of 0.45% WO₃. That is more than many of its competitors. The new mine is very different from the old facility that made Sangdong a rich mining town until 1992.

    Sangdong scores with financing partner KfW and unique offtake agreements

    The new Sangdong mine is a modern, fully networked underground project and offers real-time monitoring of geology, air quality, and rock movements. The planned and already financed processing plant is expected to deliver a WO₃ concentrate with a grade of 65%. In Phase 1, which is set to begin in 2025, Almonty will move around 640,000 tons of ore per year in the mine, and in Phase 2, this figure is expected to rise to 1.2 million tons – enough to make Almonty one of the largest non-Chinese tungsten producers. If only Western mines in geopolitically robust locations are taken into account, the project is likely to be unique.

    According to Almonty CEO Lewis Black, previous tungsten projects often failed due to volatile world market prices and unfavorable financial structures. For Sangdong, the experienced mining entrepreneur therefore opted for a different model: the combination of loans from the renowned German development bank KfW and off-take agreements, which have a price floor but benefit 100% from rising world market prices, offers the best economic conditions. While competing tungsten projects are still in the development stage, Almonty is expected to bring two mines into production within the next 12 months.

    Costs at 50% of Chinese competitors - CEO Lewis Black rings the Nasdaq bell

    While competitors, such as the tungsten project in Plymouth, UK, already have weaker geological starting conditions, Almonty outperforms the competition in terms of operational expertise. Already in the 2010s, Almonty led the Portuguese Panasqueira mine to profitability and honed its efficiency under pressure from heavily subsidized Chinese low-cost competitors. Instead of complaining, it opened a tungsten laboratory to learn more about processing this unique element. The result: when the Sangdong mine starts producing tungsten later this year, its costs will be around 50% of those of its Chinese competitors. There, too, it has now been recognized that indiscriminate government support tends to make mining companies sluggish, and subsidies for tungsten mining have been eliminated. However, this does not mean that conditions are equal – as Almonty CEO Lewis Black said in an interview with the Frankfurter Allgemeine Zeitung a few weeks ago, he believes Almonty is ten years ahead of the competition in terms of technology.**

    While shares in companies such as rare earth specialist MP Materials, in which the US government acquired a stake in the summer, have recently risen again, Almonty's shares are still trading at around their four-week low. For investors with a long-term perspective who are aware of Almonty's technological superiority, this could be an opportunity. Today, Almonty CEO Lewis Black will ring the bell to open trading on the Nasdaq. The ceremony symbolizes the development the Company has undergone over the past ten years. While investors in stocks such as Rheinmetall are increasingly doubtful about how long the boom will last, Almonty appears to be perfectly positioned. Tungsten is used in numerous applications, from defense to high-tech, and is proven to be in short supply. Only Almonty can deliver in the short term. This starting position is unique for investors.

    Watch YouTube video

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") currently hold or hold shares or other financial instruments of the aforementioned companies and speculate on their price developments. In this respect, they intend to sell or acquire shares or other financial instruments of the companies (hereinafter each referred to as a "Transaction"). Transactions may thereby influence the respective price of the shares or other financial instruments of the Company.
    In this respect, there is a concrete conflict of interest in the reporting on the companies.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.
    For this reason, there is also a concrete conflict of interest.
    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Nico Popp

    Nico Popp

    At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

    About the author



    Related comments:

    Commented by Tarik Dede on October 15th, 2026 | 05:35 CEST

    Opportunities and Risks: ASML, Almonty Industries and Lynas Rare Earths in Focus

    • ASML
    • EUV lithography system
    • Lynas Rare Earths
    • Rare earths
    • Almonty Industries
    • Tungsten

    Whether driven by interest rate concerns, geopolitical tensions or high oil prices, making money in the market is no easy task right now. In times like these, it is important to focus on the operational performance of individual companies. Businesses that deliver solid profit growth and prove resilient in the face of market headwinds may be better positioned to navigate a difficult environment. Meanwhile, the ongoing euphoria around artificial intelligence may be nearing the end of the boom. Analysts estimate that around 3% of US GDP is now flowing into the AI industry alone. This would make the current boom even larger than the stock market frenzy surrounding railway shares in the 19th century. Today, we take a closer look at ASML and examine the opportunities and risks facing Almonty Industries and Lynas Rare Earths.

    Read

    Commented by Carsten Mainitz on October 14th, 2026 | 05:30 CEST

    Tungsten, Weapons and Growth: Almonty, Rheinmetall and Deutz Under Review. Is This an Opportunity in a Megatrend?

    • Tungsten
    • Raw materials
    • Critical raw materials
    • Geopolitics
    • Defence industry
    • Armaments
    • Military
    • Supply chains
    • Investments

    The stock market is not linear. Greed and fear, excessive optimism or excessive scepticism—all of these drive markets. Only the future will tell what is cheap or expensive today. The stocks mentioned above are at precisely this point. Secure supply chains, access to raw materials and defence readiness are high on the agenda of Western governments. These long-term trends play strongly into the hands of defence companies and raw material producers. Almonty, in particular, as a producer of the critical raw material tungsten, holds a leading position in the sector. Where do the greatest opportunities lie for investors now?

    Read

    Commented by Carsten Mainitz on October 14th, 2026 | 05:25 CEST

    Who Profits When Patents Expire? The Billion-Euro Race Between Formycon, Fresenius and Pfizer

    • Biosimilar
    • FDA
    • Milestone
    • Cancer therapy
    • Pharma
    • Patents
    • Investments

    When patent protection for high-revenue biopharmaceuticals expires, a billion-euro market for follow-on products emerges. Michael Sen, head of the German healthcare group Fresenius SE, cites an impressive figure. By 2035, this could generate around EUR 180 billion in revenue. In particular, biosimilars, biotechnologically produced follow-on medicines that are highly similar in composition to the original medicine and equivalent in quality, efficacy and safety, are forecast to grow significantly. Moreover, biosimilars can strengthen competition and reduce treatment costs. Formycon stands out as a pure play. The company recently reached a crucial milestone. The US Food and Drug Administration (FDA) accepted the marketing authorisation application, the first publicly known application of its kind, for FYB206, a biosimilar candidate to the cancer medicine Keytruda, for review. Keytruda generates around USD 32 billion in annual revenue, making it the world's highest-revenue medicine. Fresenius is strengthening its positioning in the biosimilar sector through an acquisition. Pfizer needs new growth drivers. Who is best positioned for the year-end rally?

    Read